

Markus Hartenbach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1549311/publications.pdf>

Version: 2024-02-01

26
papers

1,436
citations

394421

19
h-index

526287

27
g-index

27
all docs

27
docs citations

27
times ranked

1885
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 469-478.	5.0	372
2	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. <i>Clinical Cancer Research</i> , 2018, 24, 6300-6307.	7.0	112
3	⁶⁸ Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1617-1623.	5.0	111
4	Response assessment using ⁶⁸ Ga-PSMA ligand PET in patients undergoing ¹⁷⁷ Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1063-1072.	6.4	100
5	⁶⁸ Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 235-242.	6.4	89
6	Relationship between PSA kinetics and [¹⁸ F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 271-282.	6.4	75
7	Reduced task durations in functional PET imaging with [¹⁸ F]FDG approaching that of functional MRI. <i>NeuroImage</i> , 2018, 181, 323-330.	4.2	59
8	Combined PET/MRI Improves Diagnostic Accuracy in Patients with Prostate Cancer: A Prospective Diagnostic Trial. <i>Clinical Cancer Research</i> , 2014, 20, 3244-3253.	7.0	58
9	Response assessment using [⁶⁸ Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 74-82.	2.3	49
10	Clinical outcome of standardized ¹⁷⁷ Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 713-720.	6.4	46
11	Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [⁶⁸ Ga]Ga-Pentixafor-PET/MRI. <i>Theranostics</i> , 2019, 9, 3653-3658.	10.0	42
12	Quantitative assessment of atherosclerotic plaques on ¹⁸ F-FDG PET/MRI: comparison with a PET/CT hybrid system. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1503-1512.	6.4	38
13	[¹⁸ F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2159-2169.	6.4	35
14	Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. <i>Brain Structure and Function</i> , 2018, 223, 1369-1378.	2.3	34
15	Prospective evaluation of the performance of [⁶⁸ Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2169-2177.	6.4	30
16	Performance of [⁶⁸ Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 1-10.	3.9	30
17	Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [¹¹ C]acetate PET as a prognostic marker. <i>Prostate</i> , 2015, 75, 1760-1767.	2.3	28
18	Evaluating Treatment Response of Radioembolization in Intermediate-Stage Hepatocellular Carcinoma Patients Using ¹⁸ F-Fluoroethylcholine PET/CT. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1661-1666.	5.0	28

#	ARTICLE	IF	CITATIONS
19	Prediction of response and survival after standardized treatment with 7400ÂMBq 177Lu-PSMA-617 every 4Âweeks in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1650-1657.	6.4	21
20	Reproducibility of MRI Dixon-Based Attenuation Correction in Combined PET/MR with Applications for Lean Body Mass Estimation. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1096-1101.	5.0	18
21	Thyroid and androgen receptor signaling are antagonized by β -Crystallin in prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 731-747.	5.1	17
22	Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2020, 45, 661-667.	1.3	14
23	Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. <i>European Neuropsychopharmacology</i> , 2019, 29, 711-719.	0.7	11
24	Analysis of hematological parameters as prognostic markers for toxicity and survival of 223Radium treatment. <i>Oncotarget</i> , 2018, 9, 16197-16204.	1.8	6
25	Attenuation Correction Approaches for Serotonin Transporter Quantification With PET/MRI. <i>Frontiers in Physiology</i> , 2019, 10, 1422.	2.8	5
26	Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 3692-3704.	2.2	5